An infusion pump system is disclosed. The infusion pump system includes an infusion pump and a controller device in wireless communication with the infusion pump, wherein the controller including instructions for controlling the infusion pump, wherein the instructions may be synchronized with a secure web portal.

A control circuit for a sensorless implantable blood pump configured to determine mitral valve regurgitation includes processing circuitry configured to generate an estimated blood flow waveform from the sensorless implanted blood pump and generate an alert if between an end period of diastole and a beginning period of systole a measured amplitude of the estimated blood flow waveform does not include an inflection point.

Apparatus and methods are described for use with a portion of plant material that includes at least one active ingredient. A vaporizing unit includes a heating element configured to heat the plant material, and a sensor configured to detect an indication of airflow rate through the vaporizing unit. Control circuitry is configured to receive an indication of the airflow rate through the vaporizing unit, and, in response thereto, to determine a smoking profile that is desired by the user. The control circuitry drives the heating element to vaporize the active ingredient of the plant material by heating the plant material according to the determined smoking profile. The control circuitry dynamically updates the smoking profile in response to changes in airflow rate over the course of a smoking session. Other applications are also described.

A control body is coupled or coupleable with a cartridge that is equipped with a heating element and contains an aerosol precursor composition, the control body and cartridge forming an aerosol delivery device. The control body includes a control component to control the heating element to activate and vaporize components of the aerosol precursor composition. The control body also includes a gas sensor configured to detect a presence of gas in an environment of the control body, and the gas sensor or control component are further configured to control operation of at least one functional element of the aerosol delivery device in response to the presence of gas so detected.

A system for at least partial closed-loop control of a medical condition is disclosed. The system includes at least one medical fluid pump. The medical fluid pump including a sensor for determining the volume of fluid pumped by the pump. Also, at least one continuous analyte monitor, and a controller. The controller is in communication with the medical fluid pump and the at least one continuous analyte monitor. The controller includes a processor. The processor includes instructions for delivery of medical fluid based at least on data received from the at least one continuous analyte monitor.

Embodiments of a negative pressure wound therapy systems and methods for operating the systems are disclosed. In some embodiments, a system includes a pump assembly, canister, and a wound dressing configured to be positioned over a wound. The pump assembly, canister, and the wound dressing can be fluidically connected to facilitate delivery of negative pressure to a wound. The system can be configured to efficiently deliver negative pressure in continuous and intermittent modes. The system can also be configured to gradually ramp up and down to set pressure values. The system can also be configured to detect and indicate presence of certain conditions, such as low pressure, high pressure, leak, canister full, and the like. Detection and indication of the presence of at least some of these conditions can be enabled and disabled.

Embodiments of the present invention provide for maintaining a level set of a pulmonary artery catheterization apparatus that includes a pulmonary artery pressure sensor in communication with a pulmonary artery catherization manifold affixed to a pulmonary artery catheter. The method includes calibrating leveling of the pulmonary artery pressure sensor (at the level of the right atrium) with the pulmonary artery catheterization manifold by recording a vertical level of a leveling base positioned at a common level to the manifold, relative to a vertical level of a leveling sensor positioned at a common level to the pulmonary artery pressure sensor. The method further includes monitoring a difference between the recorded vertical level of the leveling base relative to the vertical level of the leveling sensor. Finally, the method includes generating an alert in a user interface element of the leveling sensor in response to the monitored difference exceeding a threshold value.

A method of administering insulin includes receiving glucose measurements of a patient at a data processing device from a continuous glucose monitoring system. The glucose measurements are separated by a time interval. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment from a collection of subcutaneous insulin treatments. The selection is based on the glucose measurements and the patient information. The selection includes one or more of a subcutaneous standard program, a subcutaneous program without meal boluses, a meal-by-meal subcutaneous program without carbohydrate counting, a meal-by-meal subcutaneous program with carbohydrate counting, and a subcutaneous program for non-diabetic patients. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.

An infusion pump for delivery of a fluid is disclosed. The infusion pump allows a user to selectively control a flow rate of a fluid and includes a spike member that is connectable to an injection port of an intravenous fluid container.

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.